OXFORD, England, July 1, 2024 /PRNewswire/ -- The last new chronic
pain medicine was approved by regulators a decade ago, even though
1.5 billion people currently suffer chronic pain worldwide. The
challenges faced during research and development for pain
therapeutics make it a time-intensive and costly endeavour for
pharmaceutical and biotech companies, with only a 1% clinical
development success rate.
During the early development of analgesics, animal models or
cell-cultures are often used. These might give valuable insights
into preclinical biological mechanisms underlying pain, but there
is limited evidence they provide target validation for these
mechanisms in humans. Development costs remain high and clinical
trials continue in the same patient groups rather than those most
relevant for the research target.
Addressing this situation, the first precision analgesics
company, EptivA Therapeutics, partnering with digital technology
experts Infopoly Ltd., has developed Pain Cloud®.
Pain Cloud is an in-silico method, based on network biology
principles, linking open access 'large-data' for unbiased 'omic'
enrichment with Pain Cloud's Proprietary Pain Landscape®, which
hosts a wide range of data on over 1,000 distinct pain
conditions.
This approach has been validated, through a research
collaboration with Bayer Pharmaceuticals, by exploring data for
existing approved medicines, alongside other targets which failed
in the clinical development phase following positive pre-clinical
research.
Partnering with Infopoly, Pain Cloud has been enhanced with a
range of software tools to make its application as useful and
effective as possible. Its network biology algorithm can be
operated automatically, giving access to large data sets from
high-quality molecular databases, providing unbiased analyses
linking research targets to optimised disease phenotypes.
Our Personalized Analgesics® bioinformatic approach creates
thousands of nodes of data via novel human-focused network biology,
all linked to our proprietary Pain Landscape® database of thousands
of diseases.
With Pain Cloud's technology, analgesic development will be
quicker, less expensive, and more successful. It is hoped safer,
efficient, and targeted pain medications, utilizing insights from
Pain Cloud, will become available to those who need it most
soon.
Mark J Field, CEO and Co-founder of EptivA Therapeutics, says:
"Infopoly have further developed our novel methodology, enabling an
Advanced Pain Management Solutions B2B platform. By utilising Pain
Cloud, researchers can solve the cost-intensive traditional R&D
with a streamlined process to precisely match targets and
mechanisms to specific patient groups saving time and reducing
expenditure." Visit https://paincloud.ai for more
information.
Media contact:
Mark J. Field PhD MSc FRSB FIScT
Co-Founder & CEO, EptivA Therapeutics
mark@eptivatx.com
+44 (0)7565 500265
View original
content:https://www.prnewswire.co.uk/news-releases/pain-cloud-launch-a-collaboration-between-eptiva-and-infopoly-ltd-creating-an-advanced-solution-to-pain-research-302187154.html